Myosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-muscle Myosin II in Newly Diagnosed Glioblastoma

B JUPITER, Fla., May 19, 2026 /PRNewswire/ — Myosin Therapeutics, a clinical stage biotechnology company developing innovative therapies for oncology, today announced that the first…
posteditor
posteditor
Articles: 21727

Other News